Acadia Pharma (ACAD): Nuplazid KOL Follow-Up Call - Needham

October 24, 2016 8:37 AM EDT
Get Alerts ACAD Hot Sheet
Price: $31.02 -1.3%

Rating Summary:
    9 Buy, 5 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade ACAD Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Needham & Company analyst, Alan Carr, reiterated his Buy rating on shares of Acadia Pharmaceuticals (NASDAQ: ACAD) after hosting a call last week with KOL Joseph Friedman of Brown University/Butler Hospital to discuss his experience with Nuplazid.

The drug was approved by FDA for Parkinson’s Disease Psychosis in Apr and launched in May 2016. Dr. Friedman has prescribed Nuplazid for ~15 pts to date. Initial feedback from 9 pts indicates the drug has been helpful in treatment-naive pts (3/4), but not in pts who have previously responded poorly to traditional antipsychotics (0/5).

Dr. Friedman has been impressed w/ safety and tolerability profile and plans to use the drug as front-line therapy. Because onset of action is relatively slow (3-6wks), he plans to continue to use quetiapine or clozapine in pts who need psychosis symptoms addressed immediately. There have been no major hurdles w/ payer coverage.

No change to the price target of $49.

For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.

Shares of Acadia Pharmaceuticals closed at $25.34 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Needham & Company, Alan Carr

Add Your Comment